- Home
- OPOF vs TLSI Comparison
OPOF vs TLSI Comparison
Compare OPOF & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPOF
- TLSI
- Stock Information
- Founded
- OPOF 1922
- TLSI 2010
- Country
- OPOF United States
- TLSI United States
- Employees
- OPOF N/A
- TLSI N/A
- Industry
- OPOF Major Banks
- TLSI Medical Specialities
- Sector
- OPOF Finance
- TLSI Health Care
- Exchange
- OPOF Nasdaq
- TLSI Nasdaq
- Market Cap
- OPOF 200.6M
- TLSI 204.0M
- IPO Year
- OPOF N/A
- TLSI N/A
- Fundamental
- Price
- OPOF $39.63
- TLSI $5.54
- Analyst Decision
- OPOF
- TLSI Strong Buy
- Analyst Count
- OPOF 0
- TLSI 5
- Target Price
- OPOF N/A
- TLSI $10.90
- AVG Volume (30 Days)
- OPOF 17.1K
- TLSI 57.6K
- Earning Date
- OPOF 07-24-2025
- TLSI 08-13-2025
- Dividend Yield
- OPOF 1.38%
- TLSI N/A
- EPS Growth
- OPOF 55.28
- TLSI N/A
- EPS
- OPOF 1.96
- TLSI N/A
- Revenue
- OPOF $61,370,000.00
- TLSI $32,141,000.00
- Revenue This Year
- OPOF N/A
- TLSI $55.52
- Revenue Next Year
- OPOF N/A
- TLSI $54.76
- P/E Ratio
- OPOF $20.78
- TLSI N/A
- Revenue Growth
- OPOF 5.28
- TLSI 46.20
- 52 Week Low
- OPOF $13.70
- TLSI $3.50
- 52 Week High
- OPOF $40.95
- TLSI $6.08
- Technical
- Relative Strength Index (RSI)
- OPOF 61.55
- TLSI 53.07
- Support Level
- OPOF $38.51
- TLSI $5.18
- Resistance Level
- OPOF $40.32
- TLSI $5.54
- Average True Range (ATR)
- OPOF 0.74
- TLSI 0.32
- MACD
- OPOF -0.06
- TLSI 0.01
- Stochastic Oscillator
- OPOF 93.37
- TLSI 82.81
About OPOF Old Point Financial Corporation
Old Point Financial Corp functions in the financial services domain in the United States. As the holding company of The Bank and Trust, it is a nationally chartered trust and wealth management service, provider. Its suite of services includes commercial banking solutions such as loan, deposit and cash management, which are rendered through a chain of branches throughout the country. It operates through segments such as Bank, Wealth and Company.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product linesPressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.